Sugi Predict

Sugi Predict / Compounds / SCHEMBL378904

SCHEMBL378904

SCHEMBL378904

O=Cc1cc2ccc(Br)cc2nc1Cl

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.66
▸ CYP1A2 P05177 2/20 0.56
▸ CYP2C19 P33261 2/20 0.56
▸ CYP3A4 P08684 1/20 0.56
▸ CYP2D6 P10635 1/20 0.56
▸ KDM4E B2RXH2 4/20 0.45
▸ KMT2A Q03164 3/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ MAPT P10636 2/20 0.45
▸ MPI P34949 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ BACE1 P56817 2/20 0.42
▸ ERN1 O75460 1/20 0.42
▸ KDR P35968 3/20 0.40
▸ GAA P10253 1/20 0.40
▸ PABPC1 P11940 2/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ TTR P02766 1/20 0.38
▸ HTT P42858 2/20 0.37
▸ CYP2A6 P11509 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8672 0.88 CYP1A2 (0.57) ALDH1A1CYP1A2CYP2C19CYP3A4CYP2D6
SCHEMBL31345649 0.82 ALDH1A1 (0.70) ALDH1A1CYP1A2CYP2C19CYP3A4CYP2D6
SCHEMBL4488260 0.82 ALDH1A1 (0.70) ALDH1A1CYP1A2CYP2C19CYP3A4CYP2D6
SCHEMBL22982789 0.79 ALDH1A1 (0.66) ALDH1A1CYP1A2CYP2C19CYP3A4CYP2D6
SCHEMBL22494969 0.79 BACE1 (0.50) ALDH1A1CYP1A2CYP2C19KDM4EKMT2A
SCHEMBL15941760 0.79 ALDH1A1 (0.66) ALDH1A1CYP1A2CYP2C19CYP3A4CYP2D6
SCHEMBL30908496 0.79 ALDH1A1 (1.00) ALDH1A1CYP1A2CYP2C19CYP3A4CYP2D6
SCHEMBL6509 0.79 ALDH1A1 (0.66) ALDH1A1CYP1A2CYP2C19CYP3A4CYP2D6
SCHEMBL32662668 0.79 ALDH1A1 (0.66) ALDH1A1CYP1A2CYP2C19CYP3A4CYP2D6
SCHEMBL29862350 0.79 ALDH1A1 (0.66) ALDH1A1CYP1A2CYP2C19CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3833668-B1 PRMT5 INHIBITORS MERCK SHARP & DOHME LLC (US) 2025-03-19 — — EP disclosed
US-12173026-B2 PRMT5 inhibitors MERCK SHARP & DOHME LLC (US) 2024-12-24 — — US disclosed
CN-112805006-B PRMT5 inhibitors 默沙东有限责任公司 2024-09-24 — — CN disclosed
US-11993602-B2 PRMT5 inhibitors MERCK SHARP & DOHME LLC (US) 2024-05-28 — — US disclosed
US-20230062119-A1 USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR MERCK SHARP & DOHME LLC (US) 2023-03-02 — — US disclosed
US-20220363707-A1 PRMT5 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2022-11-17 — — US disclosed
US-20210277009-A1 PRMT5 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2021-09-09 — — US disclosed
WO-2021126999-A1 USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR MERCK SHARP & DOHME CORP. (US) 2021-06-24 — — WO disclosed
EP-3833355-A1 PRMT5 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2021-06-16 — — EP disclosed
EP-3833668-A1 PRMT5 INHIBITORS Merck Sharp & Dohme Corp. (US) 2021-06-16 — — EP disclosed
WO-2020033282-A1 PRMT5 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2020-02-13 — — WO disclosed
US-8778966-B2 Quinolinone derivatives as PARP and tank inhibitors JANSSEN PHARMACEUTICA, NV (BE) 2014-07-15 — — US disclosed
US-20130018017-A1 QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS VIALARD JORGE EDUARDO (BE) 2013-01-17 — — US disclosed
US-8299256-B2 Quinolinone derivatives as PARP and TANK inhibitors JANSSEN PHARMACEUTICA NV (BE) 2012-10-30 — — US disclosed
EP-2134691-B1 QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2012-01-25 — — EP disclosed
US-20100168065-A1 QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-07-01 — — US disclosed
EP-2134691-A1 QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS Janssen Pharmaceutica, N.V. (BE) 2009-12-23 — — EP disclosed
US-20090264426-A1 Bicyclic aromatic substituted pyridone derivative MSD K.K. (JP) 2009-10-22 — — US disclosed
WO-2008107478-A1 QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2008-09-12 — — WO disclosed
EP-1939194-A1 BICYCLIC AROMATIC SUBSTITUTED PYRIDONE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-07-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220363707-A1 PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 ALDH1A1 1380/4885CYP1A2 1814/4885CYP2C19 703/4885
US-12173026-B2 PRMT5 inhibitors PRMT5, PRMT1, PRMT3 ALDH1A1 1380/4885CYP1A2 1814/4885CYP2C19 703/4885
US-11993602-B2 PRMT5 inhibitors PRMT5, PRMT1, PRMT6 ALDH1A1 2400/4885CYP1A2 2495/4885CYP2C19 2546/4885
US-20100168065-A1 QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS PARP1, PARP11, PARP3 ALDH1A1 2041/4885CYP1A2 2728/4885CYP2C19 3087/4885
US-20130018017-A1 QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS PARP1, PARP11, PARP3 ALDH1A1 2041/4885CYP1A2 2728/4885CYP2C19 3087/4885
US-20210277009-A1 PRMT5 INHIBITORS PRMT5, PRMT1, PRMT6 ALDH1A1 2400/4885CYP1A2 2495/4885CYP2C19 2546/4885
US-20090264426-A1 Bicyclic aromatic substituted pyridone derivative PYCR1, CHRM1, MTR ALDH1A1 1755/4885CYP1A2 73/4885CYP2C19 353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.